Today: 20 March 2026
Subscribe
Browse Category

Pfizer 21 December 2025 - 12 March 2026

Pfizer Stock Price Today: PFE Falls 1.6% but Stays Near 52-Week High (MarketWatch)

Pfizer Stock Price Today: PFE Falls 1.6% but Stays Near 52-Week High (MarketWatch)

Pfizer shares fell 1.6% to $26.86 Thursday amid a broad U.S. market selloff as oil prices rose on Middle East tensions. The company faces pressure from declining COVID product sales and forecast 2026 profit below Wall Street estimates. China approved Pfizer’s GLP-1 weight-loss drug last week, while rival Eli Lilly announced a $3 billion China investment. Pfizer lost a legal bid in generic-drug litigation this week.
12 March 2026
···
Pfizer stock slips before the open after a run to $27.73 — here’s what’s driving PFE now

Pfizer stock slips before the open after a run to $27.73 — here’s what’s driving PFE now

Pfizer shares slipped 0.3% to $27.52 in premarket trading Wednesday after a 2.1% gain the previous session. The company agreed to a $29 million settlement with the SEC over a 2013 insider-trading case tied to SAC Capital, pending court approval. Pfizer joined Swiss biotech incubator BaseLaunch as a partner. Investors await Friday’s U.S. consumer price index report.
11 February 2026
···
Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook

Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook

Pfizer shares rose 0.8% to $27.01 by early afternoon after the company reported up to 12.3% placebo-adjusted weight loss in a Phase 2b trial of its experimental obesity drug. Investors remain cautious amid concerns over patient dropout rates and side effects. Pfizer reaffirmed its 2026 forecast, projecting $59.5–$62.5 billion in revenue and $2.80–$3.00 adjusted earnings per share.
5 February 2026
···
Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax shares fell 6.4% to $8.85 at Friday’s close, underperforming the broader market. Trading volume topped 5 million shares, above the 50-day average. Investors are watching for updates on partner-driven cash, including a $30 million upfront payment expected in Q1 2026 from a license deal. Novavax delayed its profitability target to 2028 and projects 2026 adjusted revenue of $185–$205 million.
31 January 2026
····
Pfizer stock edges up as traders brace for Feb. 3 earnings and a Fed decision

Pfizer stock edges up as traders brace for Feb. 3 earnings and a Fed decision

Pfizer shares rose 0.7% to $25.84 in Monday afternoon trading, tracking a broader U.S. stock rally ahead of major earnings and a Federal Reserve policy decision. Investors are watching for Pfizer’s Feb. 3 earnings and updates on its 2026 outlook, as the company faces falling COVID demand and looming patent expirations. Trading volume remained moderate, with no major company news released.
26 January 2026
····
Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer shares closed up 0.8% at $26.10 Thursday, trading between $25.75 and $26.31. The gain followed news of a non-exclusive deal with Novavax for access to its Matrix‑M adjuvant, worth $30 million upfront. U.S. officials have reversed universal vaccine recommendations, shifting to “shared clinical-decision-making.” Pfizer CEO Albert Bourla blamed policy rhetoric for falling vaccination rates.
23 January 2026
···
Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus

Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus

Pfizer shares fell 0.6% to $25.12 in Tuesday afternoon trading after CEO Albert Bourla discussed plans to accelerate obesity drug trials at the J.P. Morgan Healthcare Conference. Bourla said Pfizer aims to launch 10 Phase 3 trials for its Metsera portfolio by 2026 but does not expect revenue growth before 2029. Investors await the Feb. 3 earnings report for updates on the obesity pipeline and guidance.
13 January 2026
···
Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer shares fell 0.7% to $25.10 Tuesday after CEO Albert Bourla told the J.P. Morgan Healthcare Conference the cash-pay obesity market is larger than expected. Pfizer plans 10 phase 3 trials for its Metsera drugs by end-2026 but does not expect revenue growth until 2029. Investors await Feb. 3 results for updates on the obesity pipeline and 2026 strategy. Rival Novo Nordisk launched a daily oral Wegovy in the U.S. this month.
13 January 2026
····
Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

Pfizer shares closed up 1.1% at $25.18 on Friday, after leading U.S. drugmakers in January list-price hikes, including a 15% increase for its COVID vaccine Comirnaty. The stock remains below its 52-week high of $27.69. Investors await Pfizer’s Feb. 3 earnings update and monitor upcoming U.S. jobs and inflation data.
3 January 2026
····
Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes

Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes

Pfizer shares slipped 0.4% to $24.90 after hours following a report the company will raise U.S. list prices on about 80 medicines in 2026, including a 15% hike for its COVID vaccine Comirnaty. Most Pfizer increases are under 10%. U.S. stock markets were closed Thursday for New Year’s Day. Investors await Pfizer’s Feb. 3 results and 2026 outlook.
1 January 2026
···
Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

Pfizer shares fell 0.4% to $24.90 in after-hours trading after reports the company will lead U.S. drug list-price increases in 2026, including a 15% hike for its COVID vaccine. Healthcare data show Pfizer plans about 80 price increases, as drugmakers prepare for the annual January price reset under political scrutiny. Investors await further pricing updates and Pfizer’s February earnings call.
1 January 2026
···
Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

Pfizer shares edged up 0.1% to $25.03 Tuesday after TD Cowen reiterated a Hold rating and $30 price target, citing negative trends through 2030. The company projected 2026 revenue of $59.5 billion to $62.5 billion and warned of a “bumpy” period ahead as COVID demand fades and key patents expire. Shares have dropped over 50% since early 2023. Pfizer’s next earnings report is set for February 3.
30 December 2025
··
Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer shares traded near $25 on Dec. 24, 2025, valuing the company at about $142 billion amid thin holiday trading. The company’s 2026 guidance, released Dec. 16, projects revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, with growth not expected to rebound until later in the decade. Investors remain focused on drug pricing risks, pipeline progress, and looming patent expirations.
24 December 2025
···
Pfizer (PFE) Stock After Hours: What’s Moving Shares After the Dec. 23, 2025 Close—and What to Watch Before Dec. 24’s Open

Pfizer (PFE) Stock After Hours: What’s Moving Shares After the Dec. 23, 2025 Close—and What to Watch Before Dec. 24’s Open

Pfizer shares closed down 1.31% at $24.88 on December 23 after news that a patient died in a long-term trial of its hemophilia drug Hympavzi. The patient suffered a stroke and brain hemorrhage following minor surgery, according to the European Haemophilia Consortium. Trading volume was lighter than average ahead of the holiday. Pfizer said it is working with investigators and regulators to review the case.
24 December 2025
··
Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Pfizer shares traded near $25.15 on Dec. 23 after a fatal thrombotic stroke was reported in a patient on its hemophilia therapy Hympavzi, prompting scrutiny from advocacy groups. The company also issued 2026 guidance projecting revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, below analyst expectations.
23 December 2025
···
Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors Can’t Ignore

Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors Can’t Ignore

Pfizer on Dec. 22 announced a new metastatic prostate cancer research program with Flagship Pioneering and Repertoire Immune Medicines, the eighth under their alliance. The move follows Pfizer’s Dec. 16 guidance projecting flat-to-down 2026 revenue, ongoing COVID product declines, and increased R&D spending. Management warned of “bumpy” years ahead as exclusivity losses weigh on sales.
22 December 2025
····
Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wall Street Is Watching

Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wall Street Is Watching

Pfizer shares traded near $25.19 as of Dec. 20, 2025, following the company’s 2026 guidance projecting $59.5–$62.5 billion in revenue and adjusted EPS of $2.80–$3.00. The stock saw heavy volume after management cited lower COVID sales, patent expiries, and deal dilution as headwinds. U.S. drug-pricing deals and new Medicare pilot programs added pressure.
21 December 2025
····
1 2

Stock Market Today

  • Sensex surges 891 points on easing oil prices and IT stock rally
    March 20, 2026, 12:57 AM EDT. The S&P BSE Sensex jumped 891.55 points to 75,098.79 on Friday morning, led by a sharp recovery after Thursday's steep 3.26% fall, the worst in two years. Key drivers include a drop in crude oil prices-Brent crude fell 1.63% to $106.87 amid easing Middle East tensions-as well as positive global cues following assurances from U.S. and Israeli leaders about reduced attacks on Iranian energy infrastructure. Broad-based buying pushed the NSE Nifty50 up 277.90 points to 23,280.05. IT stocks led the gains, with the Nifty IT index rising 1.77%, supported by Tech Mahindra and OFSS among others. Analysts say markets are oscillating between hope and fear, but investor sentiment improved on hope of de-escalation and opportunities to buy after the recent sell-off.
Go toTop